A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|DRUG: Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|DRUG: Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
Sponsor: R-Pharm